Cellectar Biosciences, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
Cellectar Biosciences, Inc. (CLRB) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 18.07 thousand shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-04.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2026-03-04
- Cellectar Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2018-06-30 was -2.80K shares.
- Cellectar Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2018-03-31 was 4.35K shares.
- Cellectar Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2017-09-30 was 4.00 shares, a 99.91% decline year-over-year.
- Cellectar Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2017-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- Cellectar Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2025 was 18.07K shares, a 33986.79% increase from fiscal 2024.
- Cellectar Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2024 was 53.00 shares, a 562.50% increase from fiscal 2023.
- Cellectar Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2023 was 8.00 shares.
- Cellectar Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2016 was 16.15K shares, a 11.92% decline from fiscal 2015.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | 18.07K shares 10-K · filed 2026-03-04 | ||||
| 2024-12-31 | 53.00 shares 10-K · filed 2026-03-04 | 1.61K shares 10-K · filed 2025-03-13 | |||
| 2023-12-31 | 8.00 shares 10-K · filed 2025-03-13 | ||||
| 2018-06-30 | -2.80K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-10 | 1.55K shares 10-Q · filed 2018-08-10 | |||
| 2018-03-31 | 4.35K shares 10-Q · filed 2018-05-11 | ||||
| 2017-09-30 | 4.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | 4.00 shares derived: sum of 2 quarters · filed 2017-11-09 | 4.00 shares 10-Q · filed 2017-11-09 | 7.62K shares derived: sum of 4 quarters · filed 2017-11-09 | |
| 2017-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | 0.00 shares 10-Q · filed 2017-08-14 | 7.61K shares derived: sum of 3 quarters · filed 2017-08-14 | 12.07K shares derived: sum of 4 quarters · filed 2017-08-14 | |
| 2017-03-31 | 0.00 shares 10-Q · filed 2017-05-11 | 7.61K shares derived: sum of 2 quarters · filed 2017-05-11 | 12.07K shares derived: sum of 3 quarters · filed 2017-05-11 | 14.69K shares derived: sum of 4 quarters · filed 2017-05-11 | |
| 2016-12-31 | 7.61K shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | 12.07K shares derived: sum of 2 quarters · filed 2017-03-15 | 14.69K shares derived: sum of 3 quarters · filed 2017-03-15 | 16.15K shares 10-K · filed 2017-03-15 | |
| 2016-09-30 | 4.46K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | 7.08K shares derived: sum of 2 quarters · filed 2016-11-10 | 8.54K shares 10-Q · filed 2016-11-10 | ||
| 2016-06-30 | 2.62K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-11 | 4.08K shares 10-Q · filed 2016-08-11 | |||
| 2016-03-31 | 1.46K shares 10-Q · filed 2016-05-12 | ||||
| 2015-12-31 | 18.34K shares 10-K · filed 2017-03-15 | ||||
| 2014-12-31 | 1.84K shares 10-K/A · filed 2016-10-20 | ||||
| 2013-09-30 | 156.13K shares 10-Q · filed 2013-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |